WO 2004/032940 PCT/AU2003/001347
1
CLASSES OF COMPOUNDS THAT INTERACT WITH GPCRs
FIELD OF THE INVENTION
The invention provides classes of biologically active compounds that
interact in a pharmaceutically significant manner with G-Protein Coupled Receptors
(GPCRs), pharmaceutical compositions containing such compounds and methods of
treatment of humans suffering from a disorder which can be at least partially
overcome by the compounds or compositions.
BACKGROUND OF THE INVENTION
The drug discovery landscape has been transformed by the genomics
revolution. Advances in the understanding of biomolecular pathways and the roles
they play in disease will lead to vast numbers of targets for therapeutic intervention.
GPCRs represent the most important collection of therapeutic targets available.
GPCRs are proteins that tranduce signals across a cell membranc. They
consist of a single polypeptide chain that threads back and forth seven times across the
phospholipid bilayer that forms the cell membrane. The polypeptide chain has a
portion inside the cell which form a G-protein coupling domain, and a receptor
portion outside or in the cell wall. A signal molecule interacts with the receptor which
sends the signal through the membrane wall and the signal causes the G-protein
coupling domain to interact with a G protein.
Over 50% of marketed drugs target GPCRs. Whilst the druggable
extent of GPCRs numbers some 450 receptors only some 200 GPCRs have been
matched with their ligands. Orphan receptors suitable for drug targeting may
therefore number in excess of 200 receptors. These are receptors with less than
approximately 45% sequence identity to known GPCRs for which ligands have not
been identified.
The targets of current GPCR drugs include, pain and inflammation,
cancer, metabolic and gastrointestinal, cardiovascular and central nervous system
disorders.
There is a continuing demand for new therapeutics, especially as our
understanding of biological processes expands from the genomics revolution. The
aforementioned GPCRs are suitable targets for therapeutic intervention due to their
roles in such disorders as cancers, obesity and erectile dysfunction.
Considering the rate of generation and nature of the targets currently

WO 2004/032940 PCT/AU2003/001347
2
being deconvoluted by biologists, there is a need for the development of drug
candidates, designed in a rational manner to purposely interact with selected targets,
such as the GPCRs.
From a drug discovery perspective, carbohydrate pyranose and furanose
rings and their derivatives are well suited as templates. Each sugar represents a three-
dimensional scaffold to which a variety of substituents can be attached, usually via a
scaffold hydroxyl group, although occasionally a scaffold carboxyl or amino group
may be present for substitution. By varying the substituents, their relative position on
the sugar scaffold, and the type of sugar to which the substituents are coupled,
numerous highly diverse structures are obtainable.
An important feature to note with carbohydrates, is that molecular
diversity is achieved not only in the type of substituents, but also in the three
dimensional presentation. The different stereoisomers of carbohydrates that occur
naturally, offer the inherent structural advantage of providing alternative presentation
of substituents.
Employing a related methodology, Hirschmann el al (Hirschmann, R.,
et. al., J. Am. Chem. Soc., 1992, 114, 9217-9218, US 5,552,534, WO 97/28172, WO
95/11686) synthesised several compounds designed as somatostatin analogues and
integrin binders. The methodology employed by Hirschmann relied on protracted,
linear, non-combinatorial syntheses, employed exclusively non-aminated pyranoses,
and did not exploit any epimerisation chemistry to allow greater access to structural
diversity. Consequently, these compounds and methods are manifestly distinct from
this present invention.
We have developed a system that allows the chemical synthesis of
highly structurally and functionally diverse derivatised carbohydrate and
tetrahydropyran structures, of both natural and unnatural origin. The diversity
accessible is particularly augmented by the juxtaposition of both structural and
functional aspects of the molecules.
Using the axioms of this drug discovery methodology, we synthesised
several novel classes of chemotypes in an effort to develop drug candidates against
GPCR targets.

WO 2004/032940 PCT/AU2003/001347
3
SUMMARY OF THE INVENTION
It is a general object of the invention to provide compounds (hat
interact with GPCRs in a biologically significant manner,
It is an optional object of the invention to provide a pharmaceutical
formulation comprising at least one compound as described herein or a
pharmaceutically acceptable salt thereof, together with one or more pharmaceutically
acceptable carriers, diluents or excipienrs.
In one aspect the invention provides for compounds of general formula
I, that interact with GPCRs in a biologically significant manner,

General Formula 1
Wherein the ring may be of any configuration;
Z is sulphur, oxygen, CH2, C(O), C(0)HNRA, NH, NRA or hydrogen, in (he case
where Z is hydrogen then R1 is not present, RA is selected from the set defined for R1
to R5,
X is oxygen or nitrogen providing that at least one X of General Formula I is nitrogen,
X may also combine independently with one of R. to R5 to form an azide,
R1 to R5 are independently selected from the following definition which includes but
is not limited to H or an alkyl, acyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl,
arylalkyl or heteroarylalkyl substituent of 1 to 20 atoms, which is. optionally
substituted, and can be branched or linear. Typical substituents include but are not
limited to OH, NO, NO2, NH2, N3, halogen, CF3, CHF2, CFI2F, nitrile, alkoxy,
aryloxy, amidine, guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid
amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl,
aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate,
sulfonamide, phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid,

WO 2004/032940 PCT/AU2003/001347
4
hetcroaryloxy, aminoaryl, aminoheteroaryl, thioalkyl, thioaryl or thioheteroaryl, which
may optionally be further substituted, and
R6 and R7 are hydrogen, or may combine to form a carbonyl function.
In one embodiment the invention provides for compounds of general formula II that
interact with GPCRs in a biologically significant manner,

General Formula II
Wherein R1, R2, R3, R5, Z and X are defined as in General Formula I.
In a second embodiment the invention provides for compounds of general formula III
that interact with GPCRs in a biologically significant manner,

General Formula III
Wherein A is defined as hydrogen, SR1, or OR1 where R1 is defined as in General
Formula I, and
X and R2 to R5 are defined as in General Formula I.
In a preferred embodiment the invention provides for compounds of General Formula
IV that interact with GPCRs in a biologically significant manner,

WO 2004/032940 PCT/AU2003/001347
5

General Formula IV
Wherein R1-R3 are defined as in General Formula I.
In a second preferred embodiment the invention provides for compounds of General
Formula V that interact with GPCRs in a biologically significant manner,

General Formula V
Where in R1, R2 and R5 are defined as in General Formula I.
In a third preferred embodiment the invention provides for compounds of General
Formula VI that interact with GPCRs in a biologically significant manner,

General Formula VI
Wherein RA is H or combines with R2 to form an azide, and
R3, R3 and R5 are defined as in General Formula I.

WO 2004/032940 PCT/AU2003/001347
6
In a fourth preferred embodiment the invention provides for compounds General
Formula VII that interact with GPCRs in a biologically significant manner of,

General Formula VII
Wherein, R2, R3 and R5 are defined as in General Formula I.
In a fifth preferred embodiment the invention provides for compounds of General
Formula VIII that interact with GPCRs in a biologically significant manner,

General Formula VIII
Wherein R1 to R3 are defined as in General Formula 1.
In a sixth preferred embodiment the invention provides for compounds of General
Formula IX that interact with GPCRs in a biologically significant manner,


WO 2004/032940 PCT/AU2003/001347
7
General Formula IX
Wherein R2 and R5 are defined as in General Formula I.
In a seventh preferred embodiment the invention provides for compounds of General
Formula X that interact with GPCRs in a biologically significant mariner,

General Formula X
Wherein R2 and R5 are defined as in General Formula I.
In an eighth preferred embodiment the invention provides for compounds of General
Formula XI that interact with GPCRs in a biologically significant manner,

General Formula XI
Wherein R2 and R3 are defined as in General Formula I.
In a ninth preferred embodiment the invention provides for compounds of General
Formula XII that interact with GPCRs in a biologically significant manner,

WO 2004/032940 PCT/AU2003/001347
8

General Formula XII
Wherein R2 and R3 are defined as in General Formula I.
The compounds of the invention may be mixed with a pharmaceutical
acceptable carrier, adjuvant, or vehicle which may comprise a-toxic carrier, adjuvant,
or vehicle that may be administered to a patient, together with a compound of this
invention, and which does not destroy the pharmacological activity thereof.
The pharmaceutical derivative may comprise a salt, ester, salt of an
ester or other derivative of a compound of this invention which, upon administration
to a recipient-, is capable of providing, either directly or indirectly, a compound of this
invention, although no limitation is meant thereby.
Compounds of the invention may be administered orally such as by
means of a tabled, powder, liquid, emulsion, dispersion and the like; by inhalation;
topically such as by means of a cream, ointment, salve etc; and as a suppository,
although no limitation is meant thereby.

WO 2004/032940 PCT/AU2003/001347
9
Examples of the Invention
Substituents per Example Libraries 1-14


WO 2004/032940 PCT/AU2003/001347
10
Assay Conditions
GPCR radioligand binding (RLB) assays
Recombinant human receptors expressed in HEK 293 cells were used
for all experiments. Receptor membrane preparations were purchased from Perkin
Elmer BioSignal. The labelled ligand used in somatostatin GPCR RLB assays was
[125I]SST-14 and in melanocortin assays was [l25I]NDP-MSH. All assays were done
in a 96-well plate format using cither glass fiber filter, mats or filter plates. All
reagents purchased were of the highest quality.
Specific assay buffer, incubation and washing conditions were
optimized for each receptor however they all followed the same general format. The
procedures for both filter mat and filter plate formats are based on the receptor
manufacturers recommendations or those described extensively in the literature. The
procedures are briefly outlined below.
In assays where filter mats are used we incubate receptor membranes,
assay buffer and [125I] labelled ligand in 96 well microplates. Add compounds to
incubation mixture and continue incubation for optimized period. Presoak Filter mat
GF/B in 0.5 % PEI for ~2 hr at 4°C. On completion of assay mixture incubation add
additional l00µL/well of assay buffer immediately prior to filtration. Filter the assay
mixture onto the GF/B filter mat using a cell harvester. Dry the filter mats prior to
sealing them into a scintillation counting bag with scintillant. Radioactivity in each
well is detected by liquid scintillation counting.
In assays where filter plates arc used Multiscreen glass fiber filter
plates (Millipore, Cat No MAFCNOB10) are precoated with 0.5 % PHI for ~2hr at
4°C. All wells are then washed with 200 Ol/well assay buffer and filtered using the
Multiscreen Separation System. Subsequently receptor membranes, assay buffer and
labelled ligands are added to the wells and equilibrated. Compounds for testing are
then added to the mixture and incubation is continued for an optimized time. Plates
are then put into the Multiscreen Separation System and the assay mixture is filtered
through the plate under vacuum. Each well is then washed several times with assay
buffer. Plates are then dried prior to putting sealing tape onto the bottom of the plate.
Scintillant is added to each well and radioactivity measured by liquid scintillation
counting.

WO 2004/032940 PCT/AU2003/001347
11
Comparison of assay conditions for 2 different assays
MC4 SST5
Volume □L
Receptor membranes 20(1:40 40(1:40
dilution dilution of
of stock) stock)
labelled ligand (~80000 cpm) 10 40
unlabelled ligand - -
mQH2O - -
Compounds 10 20
assay buffer 10 100
Total volume (□L)
Data analysis
Raw data was analysed according to standard methods using either GraphPad Prism
software or IDDBS ActivityBase software.
Key for Assay Results Libraries 1-14
"+" Indicates inhibition greater than...50%
"-" Indicates inhibition less than...50 %

WO 2004/032940 PCT/AU2003/001347
12
Example Library 1

CompoundNumber Rl R2 R3 R4 MC4inhibition at10micromolar SST5inhibition at10micromolar
1 P1 G1 P1 P7 + +
2 P1 G2 P2 P7 - +
3 P1 A3 P3 P7 - +
4 P2 A3 P3 P7 - +
5 P3 G1 P1 P7 + -
6 P3 G2 P1 P7 + +
7 P3 A3 P1 P7 - +
8 P3 G3 P1 P7 - +
9 P3 A3 P3 P7 - +
10 P3 G2 P4 P7 - +
11 P3 A3 P4 P7 - +
12 P3 G3 P4 P7 - +
13 P4 G2 P1 P7 + +
14 P4 G2 P2 P7 + +
15 P4 G3 P2 P7 + +
16 P4 A3 P3 P7 - +
17 P4 G2 P4 P7 - +
18 P4 G3 P4 P7 - +
19 P5 Gl P1 P7 + -
20 P5 G2 P1 P7 + -
21 P6 G2 P1 P7 - +
22 P1 A3 P6 P7 - +
23 P2 A3 P6 P7 - +
24 P2 G3 P6 P7 - +
25 P3 A3 P6 P7 - +
26 P4 A3 P6 P7 - +
27 P5 A3 P6 P7 - +
28 P1 A3 P1 P7 + +
29 P1 G3 P1 P7 + +
30 P1 G3 P2 P7 + +

WO 2004/032940 PCT/AU2003/001347
13
31 P1 G2 P3 P7 - +
32 P1 G2 P4 P7 + +
33 P1P1 A3 P4 P7 + +
34 G3 P4 P7 + +
35 P2 G1 P1 P7 + +
36 P2 G2 P1 P7 + +
37 P2 A3 P1 P7 + +
38 P2 G2 P2 P7 + +
39 P2 A3 P2 P7 + +
40 P2 G3 P2 P7 + +
41 P2 G3 P3 P7 - +
42 P2 A3 P4 P7 - +
43 P2 G3 P4 P7 + +
44 P4 A3 P1 P7 - +
45 P4 G3 P1 P7 + +
46 P4 A3 P2 P7 + +
47 P4 G3 P3 P7 - +
48 P5 A3 P1 P7 - +
49 P5 G3 P1 P7 + +
50 P5 A3 P2 P7 - +
51 P5 A3 P4 P7 - +
52 P5 G3 P4 P7 - +
53 P1 A3 P1 P7 + +
54 P3 A3 P2 P7 - +
55 P4 A3 P4 P7 - +

WO 2004/032940 PCT/AU2003/001347
14
Example Library 2

CompoundNumber R1 R2 R3 R4 MC4Inhibition at10 micromolar SST5Inhibition at10micromolar
56 P1 Gl P7 P1 4- +
57 P1 G2 P7 P1 + +
58 P1 G3 P7 P1 + -
59 P1 Gl P7 P2 + -
60 P1 G2 P7 P2 - +
61 P1 A3 P7 P2 + +
62 P1 G3 P7 P2 + -
63 P1 Gl P7 P4 + -
64 P1 G2 P7 P4 + -
65 P1 A3 P7 P4 + -
66 P1 G3 P7 P4 + -
67 P2 G1 P7 P1 + -
68 P2 G2 P7 P1 + -
69 P2 A3 P7 P1 + +
70 P2 G3 P7 P1 + -
71 P2 Gl P7 P2 + -
72 P2 G2 P7 P2 + -
73 P2 A3 P7 P2 + +
74 P2 G3 P7 P2 + -
75 P2 Gl P7 P4 + -
76 P2 G2 P7 P4 + -
77 P2 A3 P7 P4 + +
78 P2 G3 P7 P4 + -
79 P3 G3 P7 P1 + -
80 P3 Gl P7 P2 + +
81 P3 A3 P7 P4 - +
82 P3 G3 P7 P4 + -
83 P4 Gl P7 P1 + -
84 P4 G2 P7 P1 + +
85 P4 A3 P7 P1 - +
86 P4 G3 P7 P1 + +
87 P4 Gl P7 P2 + +

WO 2004/032940 PCT/AU2003/001347
15
88 P4 G2 P7 P2 + +
89 P4 A3 P7 P2 + +
90 P4 G3 P7 P2 + +
91 P4 A3 P7 P3 - +
92 P4 G1 P7 P4 + -
93 P4 G2 P7 P4 + -
94 P4 A3 P7 P4 + +
95 P4 G3 P7 P4 + -
96 P5 G1 P7 P1 + -
97 P5 G2 P7 P1 + -
98 P5 A3 P7 P1 + +
99 P5 G3 P7 P1 + -
100 P5 G1 P7 P2 + -
101 P5 G2 P7 P2 + -
102 P5 A3 P7 P2 + +
103 P5 G3 P7 P2 + +
104 P5 G1 P7 P4 + -
105 P5 G2 P7 P4 + -
106 P5 A3 P7 P4 + +
107 P5 G3 P7 P4 + -
108 P1 G1 P7 P6 + -
109 P2 A3 P7 P6 - +
110 P4 G2 P7 P6 + -
111 P4 A3 P7 P6 - +
112 P6 G1 P7 P1 + -
113 P6 G2 P7 P1 + -
114 P6 A3 P7 P1 + -
115 P6 G3 P7 P2 + -
116 P6 G2 P7 P2 + -
117 P6 G3 P7 P2 + -
118 P6 A3 P7 P4 - +

WO 2004/032940 PCT/AU2003/001347
16
Example Library 3

CompoundNumber R2 R3 R4 MC4inhibition at10 micromolar SST5inhibition at10 micromolar
119 A1 P3 P3 - +
120 G1 P3 P3 + +
121 A2 P3 P3 + +
122 G2 P3 P3 + +
123 A3 P3 P3 - +
124 G3 P3 P3 + +
125 Al P3 P4 - +
126 Gl P3 P4 + +
127 A2 P3 P4 - +
128 G2 P3 P4 + +
129 A3 P3 P4 + +
130 G3 P3 P4 + +
131 Al P3 P1 - +
132 Gl P3 P1 + +
133 A2 P3 P1 + +
134 G2 P3 P1 + +
135 A3 P3 P1 + +
136 G3 P3 P1 + +
137 A1 P3 P2 + +
138 G1 P3 P2 + +
139 A2 P3 P2 + +
140 G2 P3 P2 + +
141 A3 P3 P2 + +
142 G3 P3 P2 + +
143 A1 P4 P3 - +
144 G1 P4 P3 + +
145 A2 P4 P3 + +
146 G2 P4 P3 + +
147 A3 P4 P3 - +
148 G3 P4 P3 + +
149 A1 P4 P4 - +
150 G1 P4 P4 + +
151 A2 P4 P4 + +

WO 2004/032940 PCT/AU2003/001347
17
152 G2 P4P4 P4 + +
153 A3 P4 - +
154 G3 P4 P4 + +
155 A1 P4 P1 + +
156 G1 P4 P1 + +
157 A2 P4 P1 + +
158 G2 P4 P1 + +
159 A3 P4 P1 + +
160 G3 P4 P1 + +
161 A1 P4 P2 + +
162 G1 P4 P2 + +
163 A2 P4 P2 + +
164 G2 P4 P2 + +
165 A3 P4 P2 + +
166 G3 P4 P2 + +
167 A1 P1 P3 + +
168 G1 P1 P3 + +
169 A2 P1 P3 + +
170 G2 P1 P3 + +
171 A3 P1 P3 + +
172 G3 P1 P3 + +
173 A1 P1 P4 + +
174 G1 P1 P4 + +
175 A2 P1 P4 + +
176 G2 P1 P4 + +
177 A3 P1 P4 + +
178 G3 P1 P4 + +
179 A1 P1 P1 + +
180 G1 P1 P1 + +
181 A2 P1 P1 + +
182 G2 P1 P1 + +
183 A3 P1 P1 + +
184 G3 P1 P1 + +
185 A1 P1 P2 + -
186 G1 P1 P2 + +
187 A2 P1 P2 + +
188 G2 P1 P2 + +
189 A3 P1 P2 + +
190 G3 P1 P2 + +
191 A1 P2 P3 + +
192 Gl P2 P3 + +
193 A2 P2 P3 - +
194 G2 P2 P3 + +
195 A3 P2 P3 + +
196 G3 P2 P3 + +
197 A1 P2 P4 + +

WO 2004/032940 PCT/AU2003/001347
18
198 Gl P2 P4 + +
199 A2 P2 P4 + +
200 G2 P2 P4 + +
201 A3 P2 P4 + +
202 G3 P2 P4 + +
203 Al P2 P1 + +
204 Gl P2 P1 + +
205 A2 P2 P1 + +
206 G2 P2 P1 + +
207208 A3 P2 P1 + +
G3 P2 P1 + +
209 A1 P2 P2 + +
210 Gl P2 P2 + +
211 A2 P2 P2 + +
212 G2 P2 P2 + +
Example Library 4

CompoundNumber Rl R2 R3 MC4 inhibitionat 10micromolar SST5inhibition at 10micromolar
213 P3 Al P3 - +
214 P3 Gl P3 + +
215 P3 A2 P3 - +
216 P3 G2 P3 + +
217 P3 A3 P3 - +
218 P3 G3 P3 + +
219 P3 Al P4 + +
220 P3 Gl P4 + +
221 P3 A2 P4 + +
222 P3 G2 P4 + +
223 P3 A3 P4 + +
224 P3 G3 P4 + +
225 P3 Al P1 + +
226 P3 Gl P1 + +

WO 2004/032940 PCT/AU2003/001347
19
227 P3 A2 P1 + +
228229 P3P3 G2 P1 + +
A3G3 P1 + +
230 P3 P1 + +
231 P3 A1 P2 - +
232 P3 G1 P2 + +
233 P3 A2 P2 + +
234 P3 G2 P2 + +
235 P3 A3 P2 + +
236 P3 G3 P2 + +
237 P4 G1 P3 + +
238 P4 A2 P3 - +
239 P4 G2 P3 + +
240 P4 A3 P3 - +
241 P4 G3 P3 + +
242 P4 A1 P4 + +
243 P4 G1 P4 + +
244 P4 A2 P4 + +
245 P4 G2 P4 + +
246 P4 A3 P4 + +
247 P4 G3 P4 + +
248 P4 A1 P1 + +
249 P4 G1 P1 + +
250 P4 A2 P1 + +
251 P4 G2 P1 + +
252 P4 A3 P1 + +
253 P4 G3 P1 + +
254 P4 A1 P2 + +
255 P4 G1 P2 + +
256 P4 A2 P2 + +
257 P4 G2 P2 + +
258 P4 A3 P2 + +
259 P4 G3 P2 + +
260 P5 A1 P3 - +
261 P5 G1 P3 + -
262 P5 A2 P3 - +
263 P5 G2 P3 + +
264 P5 A3 P3 - +
265 P5 G3 P3 + +
266 P5 A1 P4 - +
267 P5 G1 P4 + +
268 P5 A2 P4 + +
269 P5 G2 P4 + +
270 P5 A3 P4 + +
271 P5 G3 P4 + +
272 P5 A1 P1 + +

WO 2004/032940 PCT/AU2003/001347
20
273 P5 G1 P1 + +
274 P5 A2 P1 + +
275 P5 G2 P1 + +
276 P5 A3 P1 + +
277 P5 G3 P1 + +
278 P5 A1 P2 + +
279 P5 G1 P2 + +
280 P5 A2 P2 + +
281 P5 G2 P2 + +
282 P5 A3 P2 + +
283 P5 G3 P2 + +
284 P2 A1 P3 - +
285 P2 G1 P3 + +
286 P2 A2 P3 + +
287 P2 G2 P3 4- +
288 P2 A3 P3 - +
289 P2 G3 P3 - +
290 P2 A1 P4 - +
291 P2 G1 P4 + +
292 P2 A2 P4 - +
293 P2 G2 P4 + +
294 P2 A3 P4 + +
295 P2 G3 P4 + +
296 P2 A1 P1 - +
297 P2 G1 P1 + +
298 P2 A2 P1 + +
299 P2 G2 P1 + +
300 P2 A3 P1 + +
301 P2 G3 P1 + +
302 P2 A1 P2 + +
303 P2 G1 P2 + +
304 P2 A2 P2 - +
305 P2 G2 P2 + +
306 P2 A3 P2 - +
307 ?2 G3 P2 + +
Example Library 5


WO 2004/032940 PCT/AU2003/001347
21
CompoundNumber R1 R2 R3 MC4 inhibitionat 10 micromolar SST5inhibition at 10micromolar
308 P3 N4. E2 + -
309 P3 N4 E4 + -
310 P3 N4 E5 - +
311 P3 N4 E6 + +
312 P4 N4 El - +
313 P4 N4 E2 + +
314 P4 N4 E4 + -
315 P4 N4 E5 - +

WO 2004/032940 PCT/AU2003/001347
22
Example Library 6

CompoundNumber Rl R2 R3 MC4 inhibitionat 10micromolar SST5inhibition at10 micromolar
316 El N4 P3 - +
317 E2 N4 P3 + -
318 E4 N4 P3 + -
319 E5 N4 P3 - +
320 E6 N4 P3 + +
321 El N4 P4 - +
322 E2 N4 P4 - +
323 E4 N4 P4 + -
324 E5 N4 P4 + +
325 E6 N4 P4 + -
Example Library 7

CompoundNumber Rl R2 R3 MC4inhibition at10micromolar SST5inhibition at 10micromolar
326 El P3 N4 - +
327 E2 P3 N4 + +
328 E4 P3 N4 + -
329 E5 P3 N4 - +
330 E6 P3 N4 + +
331 El P4 N4 + +

WO 2004/032940 PCT/AU2003/001347
23
332 E6 P4 N4 + -
Example Library 8

CompoundNumber Rl R2 R3 MC4inhibition at10micromolar SST5inhibition at10micromolar
333 El P3 N4 + -
334 E2 P3 N4 + -
335 E3 P3 N4 + +
336 E5 P3 N4 + +
337 E6 P3 N4 - +
338 El P4 N4 + +
339 E2 P4 N4 + +
340 E3 P4 N4 + -
341 E5 P4 N4 + +
Example Library 9

Compound Rl R2 R3 MC4
Number Inhibition at4.0Micromolar
342 P4 E8 P2 +
343 P4 E9 P2 +
344 P4 E10 P2 +

WO 2004/032940 PCT/AU2003/001347
24
345 P4 G1 P2 +
346 P4 E8 P2 +
347 P4 E9 P2 +
348 P4 E11 P2 +
349 P4 G1 P2 +
Example Library 10

CompoundNumber Rl R2 R3 R4 MC4Inhibition a4.0Micro molar
350 P2 A2 P4 P2 +
351 P2 A2 P4 P2 +
352 P2 A2 P4 P3 +
353 P2 A2 P4 P3 +
354 P2 A2 P4 P4 +
355 P2 A2 P4 P4 +
356 P2 A2 P2 P2 +
357 P2 A2 P2 P2 +
358 P2 A2 P2 P3 +
359 P2 A2 P2 P4 +
360 P2 A2 P2 P4 +
361 P2 A2 P3 P2 +
362 P2 A2 P3 P3 +
363 P2 A2 P3 P3 +
364 P2 A2 P3 P4 +
365 P2 A3 P4 P2 +
366 P2 A3 P4 P2 +
367 P2 A3 P4 P4 +
368 P2 A3 P4 P4 +
369 P2 A3 P2 P2 +
370 P2 A3 P2 P4 +
371 P2 A3 P2 P4 +
372 P2 A3 P3 P2 +
373 P2 A3 P3 P2 +

WO 2004/032940 PCT/AU2003/001347
25
374375 P2 A3 P3 P3 +
375 P2 A3 P3 P4 +
376 P4 A2 P4 P3 +
377 P4 A2 P4 P4 +
378 P4 A2 P2 P2 +
379 P4 A2 P2 P3 +
380 P4 A2 P2 P3 +
381 P4 A2 P2 P4 +
382 P4 A2 P2 P4 +
383 P4 A2 P3 P2 +
384 P4 A2 P3 P3 +
385 P4 A2 P3 P4 +
386 P4 A3 P4 P2 +
87 P4 A3 P4 P3 +
388 P4 A3 P4 P4 +
389 P4 A3 P2 P2 +
390 P4 A3 P2 P2 +
391 P4 A3 P2 P3 +
392 P4 A3 P2 P3 +
393 P4 A3 P2 P4 +
394 P4 A3 P2 P4 +
395 P4 A3 P3 P2 +
396 P4 A3 P3 P4 +
Example Library 11

CompoundNumber Rl R2 R3 R4 MC4Inhibition at4.0Micromolar
397 P3 A2 P4 P2 +
398 P3 A2 P4 P3 +
399 P3 A2 P4 P4 +
400 P3 A2 P2 P2 +
401 P3 A2 P2 P3 +
402 P3 A2 P2 P4 +

WO 2004/032940 PCT/AU2003/001347
26
403 P3 A2 P3 P2 +
404 P3 A2 P3 P3 +
405 P3 A2 P3 P4 +
406 P3 A3 P4 P2 +
407 P3 A3 P4 P4 +
408 P3 A3 P2 P2 +
409 P3 A3 P2 P3 +
410 P3 A3 P2 P4 +
411 P3 A3 P3 P2 +
412 P3 A3 P3 P4 +
413 P2 A2 P4 P2 +
414 P2 A2 P4 P3 +
415 P2 A2 P4 P4 +
416 P2 A2 P2 P2 +
417 P2 A2 P2 P3 +
418 P2 A2 P2 P4 +
419 P2 A2 P3 P2 +
420 P2 A2 P3 P3 +
421 P2 A2 P3 P4 +
422 P2 A3 P4 P2 +
423 P2 A3 P4 P3 +
424 P2 A3 P4 P4 +
425 P2 A3 P2 P2 +
426 P2 A3 P2 P3 +
427 P2 A3 P2 P4 +
428 P2 A3 P3 P2 +
429 P2 A3 P3 P3 +
430 P2 A3 P3 P4 +
Example Library 12

Compound R1 R2 R3 R4 MC4
Number Inhibition at4.0Micromolar
431 P3 Gl P4 P2 +

WO 2004/032940 PCT/AU2003/001347
27
432 P3 G1 P4 P2 +
433 P3 G1 P4 P3 +
434 P3 G1 P4 P3 +
435 P3 G1 P4 P4 +
436 P3 G1 P2 P2 +
437 P3 G1 P2 P2 +
438 P3 G1 P2 P3 +
439 P3 G1 P2 P4 +
440 P3 G1 P2 P4 +
441 P3 G1 P1 P2 +
442 P3 G1 P1 P3 +
443 P3 G1 P1 P3 +
444 P3 G1 P1 P4 +
445 P3 G1 P1 P4 +
446 P3 G2 P4 P2 +
447 P3 G2 P4 P2 +
448 P3 G2 P4 P3 +
449 P3 G2 P4 P3 +
450 P3 G2 P4 P4 +
451 P3 G2 P4 P4 +
452 P3 G2 P2 P2 +
453 P3 G2 P2 P3 +
454 P3 G2 P2 P3 +
455 P3 G2 P2 P4 +
456 P3 G2 P2 P4 +
457 P3 G2 P1 P2 +
458 P3 G2 P1 P2 +
459 P3 G2 P1 P3 +
460 P3 G2 P1 P4 +
461 P3 G2 P1 P4 +
462 P3 G2 P1 P5 +
Example Library 13

CompoundNumber R1 R2 R3 R4 MC4 Inhibitionat 4.0

WO 2004/032940 PCT/AU2003/001347
28
Micromolar
463 P1 C1 P4 P2 +
464 P1 G1 P4 P3 +
465 P1 G1 P4 P4 +
466 P1 G1 P2 P3 +
467 P1 G1 P2 P4 +
468 P1 G1 P1 P3 +
469 P1 G1 P1 P4 +
470 P1 G2 P4 P2 +
471 P1 G2 P4 P3 +
472 P1 G2 P4 P4 +
473 P1 G2 P2 P2 +
474 P1 G2 P2 P3 +
475 P1 G2 P2 P4 +
476 P1 G2 P1 P2 +
477 P1 G2 P1 P3 +
478 P1 G2 P1 P4 +
479 P4 G1 P4 P2 +
480 P4 G1 P4 P3 +
481 P4 G1 P4 P4 +
482 P4 G1 P2 P2 +
483 P4 G1 P2 P3 +
484 P4 G1 P2 P4 +
485 P4 G1 P1 P2 +
486 P4 G1 P1 P3 +
487 P4 G1 P1 P4 +
488 P4 G2 P4 P2 +
489 P4 G2 P4 P3 +
490 P4 G2 P4 P4 +
491 P4 G2 P2 P2 +
492 P4 G2 P2 P3 +
493 P4 G2 P2 P4 +
494 P4 G2 P1 P2 +
495 P4 G2 P1 P3 +
496 P4 G2 P1 P4 +
497 P1 G3 P3 P3 +

WO 2004/032940 PCT/AU2003/001347
29
Example Library 14

CompoundNumber R1 R2 R3 MC4 Inhibitionat 1.0Micromolar
498 A2 G4 P3 +
499 A2 G4 P12 +
500 A2 G4 P13 +
501 A2 G4 P1 +
502 A2 E1 P3 +
503 A2 E1 P4 +
504 A2 E1 P12 +
505 A2 E1 P13 +
506 A1 E1 P3 +
507 A1 E1 P4 +
It should be appreciated that various other changes and modifications
can be made to any embodiment described without departing from the spirit and scope
of the invention.

30
WE CLAIM:
1. Use of a compound of general formula I, for the preparation of a
medicament for inhibiting or effecting the activity of GPCR, said compound
of formula 1 is:

wherein the ring may be of any configuration;
Z is selected from the group consisting of: sulphur, oxygen, or NRA wherein RA is
selected from the set defined for R1 to R5 or C1 to C15 acyl, C4 to C15 arylacyl
or C4 to C15 heteroarylacyl, with the proviso that both R1 and RA are not
hydrogen,
X is selected from the group consisting of: oxygen or NRA providing that at least
one X of General Formula I is NRA,

31
R1 to R5 are independently selected from the group consisting of: H, C1 to C12
alkyl, C1 to C12 alkenyl, C1 to C12 alkynyl, C1 to C12 heteroalkyl, C4 to C15
aryl, C4 to C15 heteroaryl, C4 to C15 arylalkyl or C4 to C15 heteroarylalkyl
substituent,
wherein, when X is NRA, both RA and the corresponding R1 to R5 are not
hydrogen.
2. The use as claimed in claim 1, wherein any one of RA or R1 to R5 is
substituted with a moiety selected from the group consisting of: OH, NO,
NO2, NH2, N3, halogen, CF3, CHF2, CH2F, nitrile, alkoxy, aryloxy, amidine,
guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid
amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl,
aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine,
sulfate, sulfonamide, phosphate, phosphoramide, hydrazide,
hydroxamate, hydroxamic acid, heteroaryloxy, aminoaryl,
aminoheteroaryl, thioalkyl, thioaryl or thioheteroaryl.
3. The use as claimed in claim 1, wherein the use is


32
4. The use as claimed in claim 1, wherein the use is

The use as claimed in claim 1, wherein the use is

The use as claimed in claim 1, wherein the use is


33
The use as claimed in claim 1, wherein the use is

The use as claimed in claim 1, wherein the use is

The use as claimed in claim 1, wherein the use is


34
10. The use as claimed in claim 1, wherein the use is

11. The use as claimed in claim 1, wherein the use is


35
12. The use as claimed in claim 1, wherein the use is

13. The use as claimed in claim 1, wherein the use is

14.The use as claimed in claim 1, wherein the receptor is a somatostatin
receptor.
15. The use as claimed in claim 1, wherein the receptor is a melanocortin
receptor.

36
16.The use as claimed in claim 14, wherein the use is

wherein R1, R2, R3 and R4 are selected from the group combinations of:
R1 R2 R3 R4
P1 G1 P1 P7
P1 G2 P2 P7
P1 A3 P3 P7
P2 A3 P3 P7
P3 G2 P1 P7
P3 A3 P1 P7
P3 G3 P1 P7
P3 A3 P3 P7
P3 G2 P4 P7
P3 A3 P4 P7
P3 G3 P4 P7
P4 G2 P1 P7
P4 G2 P2 P7
P4 G3 P2 P7
P4 A3 P3 P7

WO 2004/032940 PCT/AU2003/001347
37
P4 G2 P4 P7
P4 G3 P4 P7
P6 G2 P1 P7
P1 A3 P6 P7
P2 A3 P6 P7
P2 G3 P6 P7
P3 A3 P6 P7
P4 A3 P6 P7
P5 A3 P6 P7
P1 A3 P1 P7
P1 G3 P1 P7
P1 G3 P2 P7
P1 G2 P3 P7
P1 G2 P4 P7
P1 A3 P4 P7
P1 G3 P4 P7
P2 G1 P1 P7
P2 G2 P1 P7
P2 A3 P1 P7
P2 G2 P2 P7
P2 A3 P2 P7
P2 G3 P2 P7
P2 G3 P3 P7
P2 A3 P4 P7
P2 G3 P4 P7
P4 A3 P1 P7
P4 G3 P1 P7
P4 A3 P2 P7
P4 G3 P3 P7
P5 A3 P1 P7
P5 G3 P1 P7
P5 A3 P2 P7
P5 A3 P4 P7
P5 G3 P4 P7
P1 A3 P1 P7
P3 A3 P2 P7
P4 A3 P4 P7
and wherein the groups A, P and G arc as described in "Substiluents per Example
Libraries 1-14" in the specification.

38
17. The use as claimed in claim 14, wherein the use is

wherein R1, R2, R3 and R4 are selected from the group combinations of:

Rl R2 R3 R4 MC4inhibition at10micromolar
P1 G1 P1 P7 +
P3 Gl P1 P7 +
P3 G2 P1 P7 +
P4 G2 P1 P7 +
P4 G2 P2 P7 +
P4 G3 P2 P7 +
P5 Gl P1 P7 +
P5 G2 P1 P7 +
P1 A3 P1 P7 +
P1 G3 P1 P7 +
P1 G3 P2 P7 +
P1 G2 P4 P7 +
P1 A3 P4 P7 +
P1 G3 P4 P7 +
P2 Gl P1 P7 +
P2 G2 P1 P7 +
P2 A3 Pl P7 +
P2 G2 P2 P7 +
P2 A3 P2 P7 +
P2 G3 P2 P7 +
P2 G3 P4 P7 +
P4 G3 P1 P7 +
P4 A3 P2 P7 +
P5 G3 P1' P7 +

39
and wherein the groups P, G and A are as described in "Substituents per
Example Libraries 1-15" in the specification.
18.The use as claimed in claim 15, wherein the use is

wherein R1, R2, R3 and R4 are selected from the group combinations of:

R1 R2 R3 R4
P1 G1 P7 P1
P1 G2 P7 P1
P1 G3 P7 P1
P1 G1 P7 P2
P1 A3 P7 P2
P1 G3 P7 P2
P1 G1 P7 P4
P1 G2 P7 P4
P1 A3 P7 P4
P1 G3 P7 P4
P2 Gl P7 P1
P2 G2 P7 P1
P2 A3 P7 P1
P2 G3 P7 P1
P2 G1 P7 P2
P2 G2 P7 P2
P2 A3 P7 P2
P2 G3 P7 P2
P2 G1 P7 P4
P2 G2 P7 P4
P2 A3 P7 P4
P2 G3 P7 P4
P3 G3 P7 P1
P3 Gl P7 P2
P3 G3 P7 P4
P4 G1 P7 P1
P4 G2 P7 P1
P4 G3 P7 P1
P4 G1 P7 P2
P4 G2 P7 P2
P4 A3 P7 P2
P4 G3 P7 P2
P4 G1 P7 P4

40

P4 A3 P7 P4
P4 G3 P7 P4
P5 G1 P7 P1
P5 G2 P7 P1
P5 A3 P7 P1
P5 G3 P7 P1
P5 G1 P7 P2
P5 G2 P7 P2
P5 A3 P7 P2
P5 G3 P7 P2
P5 G1 P7 P4
P5 G2 P7 P4
P5 A3 P7 P4
P5 G3 P7 P4
P1 G1 P7 P6
P4 G2 P7 P6
P6 G1 P7 P1
P6 G2 P7 P1
P6 A3 P7 P1
P6 G3 P7 P2
P6 G2 P7 P2
P6 G3 P7 P2
and wherein the groups P, G and A are as described in "Substituents per
Example Libraries 1-14" in the specification.

41
19.The use as claimed in claim 14, wherein the use is

wherein R1, R2, R3 and R4 are selected from the group combinations of:

P3 G1 P7 P2P4
P3 A3 P7
P4 G2 P7 P1
P4 A3 P7 P1
P4 G3 P7 P1
P4 G1 P7 P2P2
P4 G2 P7
P4 A3 P7 P2
P4 G3 P7 P2
P4 A3 P7 P3
P4 A3 P7 P4
P5 A3 P7 P1
P5 A3 P7 P2
P5 G3 P7 P2
P5 A3 P7 P4
P2 A3 P7 P6
P4 A3 P7 P6
P6 A3 P7 P4
and wherein the groups P, G and A are as described in "Substituents per
Example Libraries 1-14" in the specification.

42
20.The use as claimed in claim 15, wherein the use is

wherein
R4, R2 and R3 are selected from the group combinations of:

R2 R3 R4
G1 P3 P3
A2 P3 P3
G2 P3 P3
G3 P3 P3
G1 P3 P4
G2 P3 P4
A3 P3 P4
G3 P3 P4

WO 2004/032940 PCT/AU2003/001347
43
G1 P3 P1
A2 P3 P1
G2 P3 P1
A3 P3 P1
G3 P3 P1
A1 P3 P2
G1 P3 P2
A2 P3 P2
G2 P3 P2
A3 P3 P2
G3 P3 P2
G1 P4 P3
A2 P4 P3
G2 P4 P3
G3 P4 P3
G1 P4 P4
A2 P4 P4
G2 P4 P4
G3 P4 P4
A1 P4 P1
G1 P4 P1
A2 P4 P1
G2 P4 P1
A3 P4 P1
G3 P4 P1
A1 P4 P2
G1 P4 P2
A2 P4 P2
G2 P4 P2
A3 P4 P2
G3 P4 P2
A1 P1 P3
G1 P1 P3
A2 P1 P3
G2 P1 P3
A3 P1 P3
G3 P1 P3
A1 P1 P4
G1 P1 P4
A2 P1 P4
G2 P1 P4
A3 P1 P4
G3 P1 P4
A1 P1 P1
G1 P1 P1
A2 P1 P1

44

G2 P1 P1
A3 P1 P1
A1 P1 P2
G1 P1 P2
A2 P1 P2
G2 P1 P2
A3 P1 P2
G3 P1 P2
A1 P2 P3
G1 P2 P3
G2 P2 P3
A3 P2 P3
G3 P2 P3
A1 P2 P4
G1 P2 P4
A2 P2 P4
G2 P2 P4
A3 P2 P4
G3 P2 P4
A1 P2 P1
G1 P2 P1
A2 P2 P1
G2 P2 P1
A3 P2 P1
G3 P2 P1
A1 P2 P2
G1 P2 P2
A2 P2 P2
G2 P2 P2
and wherein the groups P, G and A are as described in "Substituents per
Example Libraries 1-14" in the specification.

45
21.The use as claimed in claim 14, wherein the use is

wherein R4, R2 and R3 are selected from the group combinations of:

R2 R3 R4

WO 2004/032940 PCT/AU2003/001347
46


WO 2004/032940 PCT/AU2003/001347
47
A3 P4 P2
G3 P4 P2
A1 P1 P3
G1 P1 P3
A2 P1 P3
G2 P1 P3
A3 P1 P3
G3 P1 P3
A1 P1 P4
G1 P1 P4
A2 P1 P4
G2 P1 P4
A3 P1 P4
G3 P1 P4
A1 P1 P1
G1 P1 P1
A2 P1 P1
G2 P1 P1
A3 P1 P1
G3 P1 P1
A1 P1 P2
G1 P1 P2
A2 P1 P2
G2 P1 P2
A3 P1 P2
G3 P1 P2
A1 P2 P3
G1 P2 P3
A2 P2 P3
G2 P2 P3
A3 P2 P3
G3 P2 P3
A1 P2 P4
G1 P2 P4
A2 P2 P4
G2 P2 P4
A3 P2 P4
G3 P2 P4
A1 P2 P1
G1 P2 P1
A2 P2 P1
G2 P2 P1
A3 P2 P1
G3 P2 P1
A1 P2 P2
G1 P2 P2

48

A2 P2 P2
G2 P2 P2
and wherein the groups P, G and A are as described in "Substituents per
Example Libraries 1-14" in the specification.
22. The use as claimed in claim 15, wherein the use is

wherein R1, R2 and R3 are selected from the group combinations of:

R2 R3
Gl P3
G2 P3
G3 P3
Al P4
Gl P4
A2 P4
G2 P4
A3 P4
G3 P4
Al PI
Gl PI
A2 PI
G2 PI
A3 PI
G3 PI
Gl P2
A2 P2
G2 P2
A3 P2
G3 P2
Gl P3
G2 P3
/—i-» 1

WO 2004/032940 PCT/AU2003/001347
49

50

P2 A2 P1
P2 G2 P1
P2 A3 P1
P2 G3 P1
P2 A1 P2
P2 G1 P2
P2 G2 P2
P2 G3 P2
and wherein the groups P, G and A are as described in "Substituents per
Example Libraries 1-14" in the specification.
23. The use as claimed in claim 14, wherein the use is

wherein R1, R2 and R3 are selected from the group combinations of:

R1 R2 R3
P3 A1 P3
P3 G1A2 P3
P3 P3
P3 G2 P3
P3 A3 P3
P3 G3 P3
P3 A1 P4
P3 G1 P4
P3 A2 P4
P3 G2 P4
P3 A3 P4
P3 G3 P4
P3 A1 P1
P3 G1A2G2 P1
P3 P1
P3 P1

WO 2004/032940 PCT/AU2003/001347
51


52
P5 A3 P1
P5 G3 P1
P5 A1 P2
P5 G1 P2
P5 A2 P2
P5 G2 P2
P5 A3 P2
P5 G3 P2
P2 A1 P3
P2 G1 P3
P2 A2 P3
P2 G2 P3
P2 A3 P3
P2 G3 P3
P2 A1 P4
P2 G1 P4
P2 A2 P4
P2 G2 P4
P2 A3 P4
P2 G3 P4
P2 A1 P1
P2 G1 P1
P2 A2 P1
P2 G2 P1
P2 A3 P1
P2 G3 P1
P2 A1 P2
P2 G1 P2
P2 A2 P2
P2 G2 P2
P2 A3 P2
P2 G3 P2
and wherein the groups P, G and A are as described in "Substituents per Example
Libraries 1-14" in the specification.

53
24. The use as claimed in claim 15, wherein the use is

wherein R1, R2 and R3 are selected from the group combinations of:

R1 R2 R3
P3 N4 E2
P3 N4 E4
P3 N4 E6
P4 N4 E2
P4 N4 E2
and wherein the groups P, N and E are as described in "Substituents per
Example Libraries 1-14" in the specification.
25.The use of claim 14, wherein the use is


54
wherein R1, R2 and R3 are selected from the group combinations of:

R1 R2 R3
P3 N4 E5
P3 N4 E6
P4 N4 E1
P4 N4 E2
P4 N4 E5
and wherein the groups P, N and E are as described in "Substituents per
Example Libraries 1-14" in the specification.
26. The use as claimed in claim 15, wherein the use is

wherein R1, R2 and R3 are selected from the group combinations of:

R1 R2 R3
E2 N4 P3
E4 N4 P3
E6 N4 P3
E4 N4 P4
E5 N4 P4
E6 N4 P4

55
and wherein the groups P, N and E are as described in "Substituents per
Example Libraries 1-14" in the specification.
27.The use as claimed in claim 14, wherein the use is

wherein R1, R2 and R3 are selected from the group combinations of:

R1 R2 R3
E1 N4 P3
E5 N4 P3
E6 N4 P3
E1 N4 P4
E2 N4 P4
E5 N4 P4
and wherein the groups P, N and E are as described in "Substituents per
Example

WO 2004/032940 PCT/AU2003/001347
56
P2 A2 P4 P4
P2 A2 P2 P2
P2 A2 P2 P2
P2 A2 P2 P3
P2 A2 P2 P4
P2 A2 P2 P4
P2 A2 P3 P2
P2 A2 P3 P3
P2 A2 P3 P3
P2 A2 P3 P4
P2 A3 P4 P2
P2 A3 P4 P2
P2 A3 P4 P4
P2 A3 P4 P4
P2 A3 P2 P2
P2 A3 P2 P4
P2 A3 P2 P4
P2 A3 P3 P2
P2 A3 P3 P2
P2 A3 P3 P3
P2 A3 P3 P4
P4 A2 P4 P3
P4 A2 P4 P4
P4 A2 P2 P2
P4 A2 P2 P3
P4 A2 P2 P3
P4 A2 P2 P4
P4 A2 P2 P4
P4 A2 P3 P2
P4 A2 P3 P3
P4 A2 P3 P4
P4 P4 P4 P2
P4 A3 P4 P3
P4 A3 P4 P4
P4 A3 P2 P2
P4 A3 P2 P2
P4 A3 P2 P3
P4 A3 P2 P3
P4 A3 P2 P4
P4 A3 P2 P4
P4 A3 P3 P2
P4 A3 P3 P4
and wherein the groups P, and A arc as described in "Substituents per Example
Libraries 1-14" in the specification.

57
Libraries 1-14 in the specification.
20 The use as claimed in claim 15, wherein the use is

wherein R1, R2, and R3 are selected from the group combinations of:

R1 R2 R3
E2 P3 N4
E4 P3 N4
E6 P3 N4
E1 P4 N4
E6 P4 N4
and wherein the groups E P, and N are as described in " Substituents per
Example Libraries 1-14" in the specification.
29. The use as claimed in claim 14, wherein the use is

wherein R1, R2, and R3 are selected from the group combinations of:

R1 R2 R3
E1 P3 N4
E2 P3 N4
E5 P3 N4

58
and wherein the groups E, P and N are as described in " Substituents per
Example Libraries 1-14" in the specification.
30. The use as claimed in claim 15, wherein the use is

wherein R1, R2, and R3 are selected from the group combinations of:

R1 R2 R3
E1 P3 N4
E2 P3 N4
E3 P3 N4
E5 P3 N4
E1 P4 N4
E2 P4 N4
E3 P4 N4
E5 P4 N4
and wherein the groups E, P and N are as described in " Substituents per
Example Libraries 1-14" in the specification.
31. The use as claimed in claim 14, wherein the use is

wherein R1, R2, and R3 are selected from the group combinations of:

R1 R2 R3

58
E5 P3 N4
E6 P3 N4
E1 P4 N4
E2 P4 N4
E5 P4 N4

59
and wherein the groups E, P and N are as described in " Substituents per
Example Libraries 1-14" in the specification.
32. The use as claimed in claim 15, wherein the use is

wherein R1, R2, and R3 are selected from the group combinations of:

R1 R2 R3
P4 E8 P2
P4 E9 P2
P4 E10 P2
P4 G1 P2
P4 E8 P2
P4 E9 P2
P4 E11 P2
P4 G1 P2
and wherein the groups P, G and E are as described in " Substituents per
Example Libraries 1-14" in the specification.
33. The use as claimed in claim 15, wherein the use is

wherein R1, R2, R3 and R4 are selected from the group combinations of:

60
R1 R2 R3 R4
P2 A2 P4 P2
P2 A2 P4 P2
P2 A2 P4 P3
P2 A2 P4 P3
P2 A2 P4 P4

61
34. The use as claimed in claim 15, wherein the use is

wherein R1, R2, R3 and R4 are selected from the group combinations of:

62
R1 R2 R3 R4
P3 A2 P4 P2
P3 A2 P4 P3
P3 A2 P4 P4
P3 A2 P2 P2
P3 A2 P2 P3
P3 A2 P2 P4
P3 A2 P3 P2
P3 A2 P3 P3
P3 A2 P3 P4
P3 A3 P4 P2
P3 A3 P4 P4
P3 A3 P2 P2
P3 A3 P2 P3
P3 A3 P2 P4
P3 A3 P3 P2
P3 A3 P3 P4
P2 A2 P4 P2
P2 A2 P4 P3
P2 A2 P4 P4
P2 A2 P2 P2
P2 A2 P2 P3
P2 A2 P2 P4
P2 A2 P3 P2
P2 A2 P3 P3
P2 A2 P3 P4
P2 A3 P4 P4
P2 A3 P4 P3
P2 A3 P4 P4
P2 A3 P2 P2
P2 A3 P2 P3
P2 A3 P2 P4
P2 A3 P3 P2
P2 A3 P3 P3
P2 P3 P3 P4

63
and wherein the groups P, and A are as described in " Substituents per
Example Libraries 1-14" in the specification.
35. The use as claimed in claim 15, wherein the use is

wherein R1, R2, R3 and R4 are selected from the group combinations of:

R1 R2 R3 R4
P3 A2 P4 P2
P3 A2 P4 P3
P3 A2 P4 P4
P3 A2 P2 P2
P3 A2 P2 P3
P3 A2 P2 P4
P3 A2 P3 P2
P3 A2 P3 P3
P3 A2 P3 P4
P3 A3 P4 P2
P3 A3 P4 P4
P3 A3 P2 P2
P3 A3 P2 P3
P3 A3 P2 P4
P3 A3 P3 P2
P3 A3 P3 P4
P2 A2 P4 P2
P2 A2 P4 P3
P2 A2 P4 P4
P2 A2 P2 P2
P2 A2 P2 P3
P2 A2 P2 P4
P2 A2 P3 P2
P2 A2 P3 P3
P2 A2 P3 P4
P2 A3 P4 P2
P2 A3 P4 P3
P2 A3 P4 P4
P2 A3 P2 P2
P2 A3 P2 P3
P2 A3 P2 P4
P2 A3 P3 P2
P2 A3 P3 P3
P2 A3 P3 P4

64
P3 G2 P1 P5
and wherein the groups P, and G are as described in " Substituents per Example
Libraries 1-14" in the specification.
36. The use as claimed in claim 15, wherein the use is

wherein R1, R2, R3 and R4 are selected from the group combinations of:
R1 R2 R3 R4
P1 G1 P4 P2
P1 G1 P4 P3
P1 G1 P4 P4
P1 G1 P2 P3
P1 G1 P2 P4
P1 G1 P1 P3
P1 G1 P1 P4
P1 G2 P4 P2
P1 G2 P4 P3
P1 G2 P4 P4
P1 G2 P2 P2
P1 G2 P2 P3
P1 G2 P2 P4
P1 G2 P1 P2
P1 G2 P1 P3
P1 G2 PI P4
P4 G1 P4 P2
P4 G1 P4 P3
P4 G1 P4 P4
P4 G1 P2 P2
P4 G1 P2 P3
P4 G1 P2 P4
P4 G1 P1 P2
P4 G1 P1 P3
P4 G1 P1 P4
P4 G2 P4 P2
P4 G2 P4 P3
P4 G2 P4 P4
P4 G2 P2 P2

65
P4 G2 P2 P3
P4 G2 P2 P4
P4 G2 P1 P2
P4 G2 P1 P3
P4 G2 P1 P4
P1 G3 P3 P3
and wherein the groups P, and G are as described in " Substituents per Example
Libraries 1-14" in the specification..
37. The use as claimed in claim 15, wherein the use is

wherein R1, R2, and R3 are selected from the group combinations of:

R1 R2 R3
A2 G4 P3
A2 G4 P12
A2 G4 P13
A2 G4 P1
A2 E1 P3
A2 E1 P4
A2 E1 P12
A2 E1 P13
A1 E1 P3
A1 E1 P4
and wherein the groups P, A and E are as described in " Substituents per
Example Libraries 1-14" in the specification.
66

Use of a compound of general formula 1, for the preparation of a medicament for
inhibiting or effecting the activity of GPCR, said compound of formula 1 is:

wherein the ring may be of any configuration;
Z is selected from the group consisting of: sulphur, oxygen, or NRA wherein RA is
selected from the set defined for R1 to R5 or C1 to C15 acyl, C4 to C15 arylacyl
or C4 to C15 heteroarylacyl, with the proviso that both R1 and RA are not
hydrogen,
X is selected from the group consisting of: oxygen or NRA providing that at least
one X of General Formula 1 is NRA,
R1 to R5 are independently selected from the group consisting of: H, C1 to C12
alkyl, C1 to C12 alkenyl, C1 to C12 alkynyl, C1 to C12 heteroalkyl, C4 to C15
aryl, C4 to C15 heteroaryl, C4 to C15 arylalkyl or C4 to C15 heteroarylalkyl
substituent,
wherein, when X is NRA, both RA and the corresponding R1 to R5 are not
hydrogen